Gowell

Gowell (also known as Gowell Pharma or Guowei Pharmaceutical) is a comprehensive Chinese biopharmaceutical company integrating research and development, manufacturing, and commercialization. Established in 2005 and headquartered in Chengdu, China, the company specializes in high-end generic chemical drugs, high-purity Omega-3 fish oil formulations, and innovative therapeutics. Through its dedicated innovative R&D center, TechGowell, the company has built a robust pipeline of small interfering RNA (siRNA) and oral peptide therapeutics. Gowell's proprietary platforms, including the SilenceSeeker multi-omics platform and a lung epithelium-targeting ligand platform, enable the development of targeted therapies for respiratory, cardiovascular, and renal diseases. Its lead innovative assets include GW863, an oral peptide in Phase II clinical trials for chronic kidney disease-associated pruritus, and GW906, an AGT-targeting siRNA for hypertension licensed to Salubris Pharmaceuticals.